CN113166024B - 芳族化合物及其医药用途 - Google Patents

芳族化合物及其医药用途

Info

Publication number
CN113166024B
CN113166024B CN201980067283.2A CN201980067283A CN113166024B CN 113166024 B CN113166024 B CN 113166024B CN 201980067283 A CN201980067283 A CN 201980067283A CN 113166024 B CN113166024 B CN 113166024B
Authority
CN
China
Prior art keywords
group
atoms
alkyl
methyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980067283.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN113166024A (zh
Inventor
T.斯克杰雷特
D.A.弗雷泽
H.H.斯泰尼格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Priority to CN202510894488.5A priority Critical patent/CN120923343A/zh
Publication of CN113166024A publication Critical patent/CN113166024A/zh
Application granted granted Critical
Publication of CN113166024B publication Critical patent/CN113166024B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/64—Monocyclic acids with unsaturation outside the aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/28—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • C07C69/16—Acetic acid esters of dihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201980067283.2A 2018-10-11 2019-10-10 芳族化合物及其医药用途 Active CN113166024B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510894488.5A CN120923343A (zh) 2018-10-11 2019-10-10 芳族化合物及其医药用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862744461P 2018-10-11 2018-10-11
US62/744,461 2018-10-11
PCT/IB2019/001139 WO2020074964A1 (en) 2018-10-11 2019-10-10 Romatic compounds and pharmaceutical uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510894488.5A Division CN120923343A (zh) 2018-10-11 2019-10-10 芳族化合物及其医药用途

Publications (2)

Publication Number Publication Date
CN113166024A CN113166024A (zh) 2021-07-23
CN113166024B true CN113166024B (zh) 2025-07-18

Family

ID=68655570

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980067283.2A Active CN113166024B (zh) 2018-10-11 2019-10-10 芳族化合物及其医药用途
CN202510894488.5A Pending CN120923343A (zh) 2018-10-11 2019-10-10 芳族化合物及其医药用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510894488.5A Pending CN120923343A (zh) 2018-10-11 2019-10-10 芳族化合物及其医药用途

Country Status (16)

Country Link
US (2) US12473249B2 (enExample)
EP (1) EP3864001A1 (enExample)
JP (2) JP2022504707A (enExample)
KR (1) KR20210091150A (enExample)
CN (2) CN113166024B (enExample)
AU (2) AU2019358595B2 (enExample)
CA (1) CA3112073A1 (enExample)
CL (1) CL2021000846A1 (enExample)
CO (1) CO2021006087A2 (enExample)
EA (1) EA202190890A1 (enExample)
IL (1) IL282134A (enExample)
MA (1) MA53188A1 (enExample)
MX (1) MX2021003750A (enExample)
PH (1) PH12021550744A1 (enExample)
SG (1) SG11202103011YA (enExample)
WO (1) WO2020074964A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023065200A1 (en) * 2021-10-21 2023-04-27 Givaudan Sa Organic compounds
WO2024206117A1 (en) 2023-03-24 2024-10-03 Northsea Therapeutics B.V. Benzoic acid derivatives for use in methods of treating intestinal failure-associated liver disease in children

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100341A2 (en) * 2001-06-12 2002-12-19 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EP1535915A1 (en) * 2002-09-06 2005-06-01 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
WO2005054243A1 (en) * 2003-12-05 2005-06-16 Actelion Pharmaceuticals Ltd Diazabicyclononene derivatives and their use as renin inhibitors
WO2006066894A1 (en) * 2004-12-24 2006-06-29 Ctg Pharma S.R.L. Compounds for treating metabolic syndrome
WO2007051995A2 (en) * 2005-11-03 2007-05-10 Astrazeneca Ab Tert-butylammonium salt or adamntylammonium salt of ortho-substituted benzoic acid derivatives
WO2007093364A1 (en) * 2006-02-15 2007-08-23 Sanofi-Aventis Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
WO2008151211A1 (en) * 2007-06-05 2008-12-11 Sanofi-Aventis Substituted benzoylamino-indan-2-carboxylic acids and related compounds
WO2011048082A1 (en) * 2009-10-20 2011-04-28 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
WO2011064350A1 (en) * 2009-11-26 2011-06-03 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
WO2013173441A2 (en) * 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
WO2017042557A1 (en) * 2015-09-07 2017-03-16 Manchester Metropolitan University Glycomimetics for use for the treatment of vascular calcification and/or endothelial dysfunction

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210266A (en) * 1987-12-03 1993-05-11 Dainippon Pharmaceutical Co., Ltd. N-substituted mercaptopropanamide derivatives
EP0637957B1 (de) 1992-04-28 1997-07-23 Fresenius AG Verwendung einer omega-3-fettsäuren enthaltenden emulsion zur herstellung eines parenteral zu verabreichenden arzneimittels zur behandlung von entzündlichen erkrankungen
DK1900364T3 (da) 2001-04-18 2014-01-13 Prometic Biosciences Inc Fedtsyrer, glycerider og analoger med medium kædelængde som neutrofile overlevelses- og aktiveringsfaktorer
AU2004210082B2 (en) * 2003-02-06 2011-03-17 Dompe' Farmaceutici S.P.A. 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them
BRPI0407276A (pt) 2003-02-07 2006-01-31 Prometic Biosciences Inc ácidos graxos, glicerìdeos e análogos com comprimento de cadeia médio, como estimulantes de eritropoiese
ES2530235T3 (es) * 2003-02-13 2015-02-27 Wellstat Therapeutics Corporation Compuestos para el tratamiento de trastornos metabólicos
PL1648851T3 (pl) 2003-07-25 2007-09-28 Prometic Biosciences Inc Wytwarzanie soli średniołańcuchowych kwasów tłuszczowych z metalami
ES2372694T3 (es) * 2003-10-15 2012-01-25 OSI Pharmaceuticals, LLC Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina.
AP2007003939A0 (en) 2004-09-03 2007-04-30 Prometic Biosciences Inc Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides
US8071580B2 (en) 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis
EA200700741A1 (ru) 2004-10-01 2007-08-31 Прометик Байосайенсиз Инк. Жирные спирты со средней длиной цепи как стимуляторы гематопоэза
TW200724138A (en) * 2005-03-29 2007-07-01 Sk Corp Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use
CN101218199A (zh) 2005-05-09 2008-07-09 阿斯利康(瑞典)有限公司 新化合物ⅰ
WO2008016007A1 (fr) 2006-07-31 2008-02-07 Meiji Seika Kaisha, Ltd. INHIBITEUR DE LA MÉTALLO-β-LACTAMASE
JP5526018B2 (ja) * 2007-03-21 2014-06-18 エミスフェアー・テクノロジーズ・インク アリルオキシおよびアルキルオキシ安息香酸送達薬剤
US9532962B2 (en) 2007-11-02 2017-01-03 Prometic Pharma Smt Limited Medium-chain length fatty acids and glycerides as nephroprotection agents
JP5473937B2 (ja) 2007-12-19 2014-04-16 プロメティック・バイオサイエンシーズ・インコーポレイテッド 膵臓癌の治療のためのゲムシタビンと併用した中鎖脂肪酸、その塩およびトリグリセリド
KR20100135793A (ko) * 2008-03-13 2010-12-27 바스프 에스이 이량체 벤질리덴 말로네이트
CN102088965B (zh) 2008-05-13 2013-05-08 根梅迪卡治疗公司 水杨酸盐(酯)缀合物在制备用于治疗代谢性病症的药物中的应用
JP2012503595A (ja) * 2008-07-28 2012-02-09 シダンスク ユニバーシティ 代謝病の治療用の化合物
EP2427416B1 (en) 2009-05-04 2016-03-09 Prometic Pharma Smt Limited Substituted aromatic compounds and pharmaceutical uses thereof
KR101783817B1 (ko) * 2009-05-08 2017-10-23 프로노바 바이오파마 너지 에이에스 심혈관 질병, 대사 질병, 및 염증성 질환 분야관련 질병의 치료를 위한 다중 불포화 지방산
TWI572352B (zh) 2012-03-01 2017-03-01 波麥堤克藥學Ｓｍｔ有限公司 用於製備具中鏈長度之脂肪酸的三酸甘油酯之方法
TWI689490B (zh) 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
TWI742541B (zh) 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
WO2015179697A1 (en) 2014-05-21 2015-11-26 Taxis Pharmaceuticals, Inc. Compounds for the treatment of bacterial infections
SG11201702812PA (en) 2014-10-10 2017-05-30 Prometic Pharma Smt Ltd Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes
KR102793841B1 (ko) 2018-05-08 2025-04-11 가부시키가이샤 아데카 화합물, 잠재성 첨가제, 조성물, 경화물, 경화물의 제조 방법 및 조성물의 제조 방법

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100341A2 (en) * 2001-06-12 2002-12-19 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EP1535915A1 (en) * 2002-09-06 2005-06-01 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
WO2005054243A1 (en) * 2003-12-05 2005-06-16 Actelion Pharmaceuticals Ltd Diazabicyclononene derivatives and their use as renin inhibitors
WO2006066894A1 (en) * 2004-12-24 2006-06-29 Ctg Pharma S.R.L. Compounds for treating metabolic syndrome
WO2007051995A2 (en) * 2005-11-03 2007-05-10 Astrazeneca Ab Tert-butylammonium salt or adamntylammonium salt of ortho-substituted benzoic acid derivatives
WO2007093364A1 (en) * 2006-02-15 2007-08-23 Sanofi-Aventis Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
WO2008151211A1 (en) * 2007-06-05 2008-12-11 Sanofi-Aventis Substituted benzoylamino-indan-2-carboxylic acids and related compounds
WO2011048082A1 (en) * 2009-10-20 2011-04-28 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
WO2011064350A1 (en) * 2009-11-26 2011-06-03 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
WO2013173441A2 (en) * 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
WO2017042557A1 (en) * 2015-09-07 2017-03-16 Manchester Metropolitan University Glycomimetics for use for the treatment of vascular calcification and/or endothelial dysfunction

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
"A Formal Synthesis of Crinipellin B Based on the Arene-Alkene meta-Photocycloaddition Reaction;WENDER P A ET AL;TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM;第 39卷(第 47期);8589-8592 *
A Thermotropic Mesophase Comprised of Closed Micellar Aggregates of the Normal Type;Carsten Tschierske , et al;Angewandte Chemie International Edition;第41卷(第4期);628-631 *
Carboxylate-directed C–H allylation with allyl alcohols or ethers;Xiao-Qiang Hu，et al;Chemical Science;第9卷;5289-5294 *
Cobalt-Catalyzed ortho-Alkylation of Secondary Benzamide with Alkyl Chloride through Directed C−H Bond Activation;Chen, Quan，et al;Journal of the American Chemical Society;第133卷(第3期);428–429 *
DeGraw, J. I.,etal .Potential antileprotic agents. 3. Inhibition of mycobacterial dihydrofolic reductase by 2,4-diamino-5-methyl-6-alkylquinazolines. Journal of Medicinal Chemistry.1974,第17卷(第7期),762–764. *
Kung, P.-P.,et al.Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors.Journal of Medicinal Chemistry.2016,第59卷(第18期), 8306–8325. *
Ligand-Accelerated ortho-C–H Alkylation of Arylcarboxylic Acids using Alkyl Boron Reagents;Peter s. thuy-bounn，et al;Journal of the American Chemical Society;第135卷(第135期);17508-17513 *
Long-Range Olefin Isomerization Catalyzed by Palladium(0) Nanoparticles;Le Thi Ngoc Chuc， et al;ACS Omega;第2卷(第2期);698–711 *
Novel heparin/heparan sulfate mimics as inhibitors of HGF/SF-induced MET activation.;Eun-Ang Raiber, et al;Bioorg. Med. Chem. Lett.;第17卷(第22期);6321–6325 *
Novel structures derived from 2AA2-pyridyl)methylUthiolU-1 H-benzimidazoles as anti-Helicobacter pylori agents, part 1;KHLER T C ET AL;JOURNAL OF MEDICINAL CHEMISTRY AMERICAN CHEMICAL SOCIETY;第45卷(第19期);4282-4299 *
Santra, Sougata,et al. Role of Polar Solvents for the Synthesis of Pillar.arenes.RSC Adv..2015,第5卷104284-104288. *
Small Macrocycles As Highly Active Integrin α2β1 Antagonists;Halland, Nis , et al.;ACS Medicinal Chemistry Letters,;第5卷(第2期);193-198 *
STN检索报告;Aurora Fine Chemicals等提供的产品目录;《数据库REGISTRY（在线）》;CAS登记号：1557804-99-5等 *
Substituted Imidazoles as Glucagon Receptor Antagonists;Linda L. Chang, et al;Bioorganic & Medicinal Chemistry Letters;第11卷(第18期);2549–2553 *
Synergistic Palladium-Catalyzed C(sp3)H Activation/C(sp3)O Bond Formation: A Direct, Step-Economical Route to Benzolactones;Novák, P., et al.;Angewandte Chemie International Edition;第50卷(第51期);12236–12239 *
Synthesis and Thermal Properties for 4-(4-Alkoxyphenoxycarbonyl)phenyl 3-Alkoxy-2-X-benzoates;Okamoto, Hiroaki, et, al;Molecular Crystals and Liquid Crystals;第439卷(第1期);221–227 *
Synthesis of Dialkylaminoalkyl Esters of Sterically Hindered 4-Alkoxybenzoic Acids;Honkanen E , Clas Tegnér, Willman N E , et al;.Acta Chemica Scandinavica;第13卷(第6期);1189-1192 *
Synthesis of Perfluoroalkylated Benzenes and Pyridines through Cationic Rh(I)/Modified BINAP-Catalyzed Chemo- and Regioselective [2 + 2 + 2] Cycloaddition;Tanaka, Ken , et al;Organic Letters;第9卷(第10期);1907-1910 *
Synthesis of small molecule inhibitors of the orphan nuclear receptor steroidogenic factor-1 (NR5A1) based on isoquinolinone scaffolds;Roth, J., etal.;Bioorganic & Medicinal Chemistry Letters;第18卷(第8期);2628–2632 *
Synthesis of the aromatic unit of calicheamicin γ1I;Hu, Yong-Zhou, et al;Journal of the Chemical Society, Perkin Transactions;第1卷(第9期);1421–1424 *
The Pyrethrins and Related Compounds. Part XXVIII: Alkenyl- and Alkynyl-substituted Benzyl Esters;MICHAEL ELLIOTT ET AL;SCIENCE;第17卷(第6期);691-700 *

Also Published As

Publication number Publication date
KR20210091150A (ko) 2021-07-21
CN120923343A (zh) 2025-11-11
AU2019358595A1 (en) 2021-05-27
CN113166024A (zh) 2021-07-23
CA3112073A1 (en) 2020-04-16
SG11202103011YA (en) 2021-04-29
JP2022504707A (ja) 2022-01-13
EP3864001A1 (en) 2021-08-18
JP2024122966A (ja) 2024-09-10
CL2021000846A1 (es) 2021-11-12
US20260184664A1 (en) 2026-07-02
MA53188A1 (fr) 2021-12-31
US12473249B2 (en) 2025-11-18
US20210380521A1 (en) 2021-12-09
IL282134A (en) 2021-05-31
WO2020074964A1 (en) 2020-04-16
PH12021550744A1 (en) 2022-02-21
BR112021006907A2 (pt) 2021-09-08
AU2019358595B2 (en) 2025-04-17
EA202190890A1 (ru) 2021-09-10
AU2025205518A1 (en) 2025-08-07
MX2021003750A (es) 2021-06-15
CO2021006087A2 (es) 2021-08-09

Similar Documents

Publication Publication Date Title
CN101137639B (zh) 类黄酮化合物及其用途
JP2021183628A (ja) カルビドパおよびｌ−ドーパプロドラッグならびにそれらの使用方法
WO2021036514A1 (zh) 一类PPARγ/δ双重激动剂、其制备方法及其作为药物的用途
JP2024122966A (ja) 芳香族化合物およびその医薬用途
JP2026074199A (ja) アデノシン受容体アンタゴニストおよびその使用
MX2010012712A (es) Co-cristales de duloxetina e inhibidores de cox para el tratamiento del dolor.
US20070060544A1 (en) 4-Nitro-2-[(4'-methoxy)-phenoxy]-methanesulfonanilide derivatives and their pharmaceutical use
WO2006066894A1 (en) Compounds for treating metabolic syndrome
WO2001060354A1 (en) Cancer remedy comprising anthranilic acid derivative as active ingredient
US20090036516A1 (en) Compounds for treating metabolic syndrome
JP2004510770A (ja) ７−カルボキシフラボン誘導体、調製法および治療適用
JP2011527340A (ja) 経口活性クルクミノイド化合物
CH679583A5 (enExample)
JP2022542613A (ja) ヒトａｔｇｌの阻害剤
KR101360579B1 (ko) 신규 페닐초산 유도체
WO2014124208A1 (en) NSAIDs DERIVATIVES AND USES THEREOF
BR112021006907B1 (pt) Compostos aromáticos, composição farmacêutica e usos da referida composição
CN101903352A (zh) 取代的3-羟基吡啶系化合物及其药物组合物
BR122025017301A2 (pt) Compostos aromáticos, composição e usos farmacêuticos destes
CN112574172A (zh) 一种没食子酸硫化氢衍生物及其制备方法及医药用途
CN115583890B (zh) 一种治疗血脂异常的药物及其用途
CN115417830B (zh) 一种乙烷-1,2-双(3-芳基丙烯酸酯)类化合物及其在药物制备中的应用
KR850001224B1 (ko) 2, 4-디옥사 이클로헥사논 유도체의 제조방법
CN106946851B (zh) 一种用于预防和治疗肾结石的药物
WO2017068052A1 (en) Derivatives of nonsteroidal anti-inflammatory drugs

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant